

7th International Congress of Clinical Chemistry
Geneva (Switzerland)/Evian (France), September 8-13, 1969
General Editor: M. Roth, Geneva

Vol. 3

Hormones, Lipids and Miscellaneous

Editors: J.-P. FELBER, Lausanne, and J.-J. SCHEIDEGGER, Geneva

With 235 figures and 71 tables.



1974年10月4日


7th International Congress of Clinical Chemistry
Geneva (Switzerland)/Evian (France), September 8-13, 1969
General Editor: M. Roth, Geneva

Vol. 3

Hormones, Lipids and Miscellaneous

Editors: J.-P. FELBER, Lausanne, and J.-J. SCHEIDEGGER, Geneva

With 235 figures and 71 tables



19

70

S. KARGER · BASEL · MÜNCHEN · PARIS · NEWYORK

Originally published by S. Karger AG, Basel, Switzerland
Distributed exclusively in the United States of America and Canada
by University Park Press, Baltimore, Maryland

Library of Congress Catalog Card Number 79-145821
International Standard Book Number (ISBN) 0-8391-0591-6

7th International Congress of Clinical Chemistry
Geneva (Switzerland)/Evian (France), September 8-13, 1969
General Editor: M. Roth, Geneva

Vol. 1: Methods in Clinical Chemistry. Editor: M. ROTH, Geneva.
XIV+321 p., 142 fig., 49 tab., 1970.

Vol. 2: Clinical Enzymology. Editors: J. FREI and M. JEMELIN, Lausanne.
XIV+204 p., 66 fig., 49 tab., 1970.

Vol. 3: Hormones, Lipids and Miscellaneous. Editors: J.-P. FELBER, Lausanne, and
J.-J. SCHEIDEGGER, Geneva.
XIV+474 p., 235 fig., 71 tab., 1970.

Vol. 4: Digestion and Intestinal Absorption. Editors: P. HORE and G. SEMENZA, Zurich.
XVIII+134 p., 49 fig., 25 tab., 1970.

S. Karger AG, Arnold-Böcklin-Strasse 25, CH-4000 Basel 11 (Switzerland)

All rights, including that of translation into other languages, reserved.
Photomechanic reproduction (photocopy, microcopy) of this book or parts thereof without
special permission of the publishers is prohibited.

©

Copyright 1970 by S. Karger AG, Verlag für Medizin und Naturwissenschaften, Basel
Printed in Switzerland by Imprimerie Corbaz SA, Montreux
Blocks: Steiner & Co., Basel

Preface

This volume gathers a number of papers relating to the clinical chemistry of hormones. Readers interested in peptide hormones will particularly appreciate the chapters on radioimmunoassays which include contributions from some of the best specialists of this rapidly developing field.

The chapter on lipids contains studies made on humans under experimental conditions. The remainder of the book consists of contributions to the symposium on detection of metabolic inborn errors, and of a number of papers assembled under the title "miscellaneous", some of which have the merit of dealing with unusual aspects of clinical chemistry.

We thank Professor J. P. Felber who organized and edited the symposia on radioimmunoassays in such an excellent manner.

M. ROTH
General Editor

Contents Vol. 1-4

Vol. 3: Hormones, Lipids and Miscellaneous

- Hormones 10

RUCHELMAN, M. W. and ANDERSON, D. E. (Houston): Endocrine Abnormalities in Human Breast Cancer	1
KAISER, E.; WERNERS, P. H.; VAN DER CRABBen, H. und WERNER, Ch. (Düsseldorf): Neuer Hormon-Belastungstest bei Plazenta-Insuffizienz	6
ADLERCREUTZ, H.; IKONEN, M. and LUUKKAINEN, T. (Helsinki): Gas Chromatographic and Mass Spectrometric Identification of Oestrogens in Pregnancy Plasma	14
McEvoy, D.; HOPKINS, L. and MARTIN, MARY J. (Philadelphia): Simultaneous Assay of Plasma Cortisol and 11-Desoxycortisol During a Metirapone Test	24
SCHLÜTZ, G.-O. und BOSCH, I. (Damaskus): Eine modifizierte Pileggi-Kessler Nassveraschungsausschlusstechnik zur quantitativen chemischen Bestimmung organischer Jodverbindungen im Serum Thyroxin (T ₄) und Trijodthyronin (T ₃)	35
JEMELIN, M.; FREI, J. and SCAZZIGA, B. (Lausanne): Leukocyte Energy Metabolism. IV. Oxidative Phosphorylation in Hyperthyroid Leukocytes	44
ESCHWEGE, E.; CLAUDE, J. R.; PATOIS, E.; RICHARD, J. L.; ROSSELIN, G. and WARNET, J. M. (Villejuif): Epidemiological Study of Glycemia During the Oral Glucose Load Test 0-2 h	47
SALWAY, J. G. and WATKINS, P. J. (Birmingham): A Simple and Rapid Method for the Determination of Acetoacetate and its Usefulness in the Control of Diabetes	58
CHMELAŘ, M. and CHMELAŘOVÁ, M. (Geneva): Defect of Peripheral Tissue Receptor for Insulin and its Importance in Pathogenesis of Diabetes Mellitus	66
GOLDSTEIN, M., JOH, T. H. and GANG, H. (New York): Some Aspects of the Biosynthesis of Catecholamines in Adrenal Glands and in Pheochromocytoma and Neuroblastoma Tumors	78

Symposium on Radioimmunoassays

FELBER, J.-P. (Lausanne): Introduction	88
BERSON, S. A., and YALOW, R. S. (New York): Introduction to the Symposium on Radioimmunoassay. General Principles.	89
YALOW, R. S. and BERSON, S. A. (New York): Radioimmunoassay Methods. Application to Different Peptide Hormones	108

Methodology

AUBERT, M. L. (Lausanne): Iodination and Purification of Polypeptide Hormones. Importance of Purity Analysis Techniques	126
ROSSELIN, G.; DOLAIS, J. and FREYCHET, P. (Paris): Adsorbents in Hormone Assay	136
Discussion by P. FRANCHIMONT (Liège):	147
QUABBE, H.-J. (Berlin): Double Antibody Separation Technique	148
CATT, K.J. (Bethesda, Md.): Solid-Phase Radioimmunoassay.	155
BAUMANN, J. B. and GIRARD, J. (Basle): Study on the Quality of an Antiserum Required for its Use in the Solid Phase Antibody Technique	162
GIRARD, J. (Basle): Non-Specificity and Incubation Damage	164

Clinical Application of Radioimmunoassays

FELBER, J.-P. (Lausanne): Clinical Applications of the Insulin Radioimmunoassay	168
LEMARCHAND-BÉRAUD, Th. (Lausanne): Clinical Application of TSH Determination by Radioimmunoassay	173
DOLAIS, J. and ROSSELIN, G. (Paris): HFSH and HLH Radioimmunological Assay During the Diurnal Cycle, Ovulation and the Suppression of the Gonadotropic Pituitary Effect	181
FRANCHIMONT, P. (Liège): Action of Testosterone on Serum FSH and LH Levels in Men	196
SCHUURS, A.H.W.M.; KELLER, P. J. and THOMAS, K. (Oss): A Modified Haemagglutination Inhibition Test for Estimating LH in Unconcentrated Urine; Comparison of the Method with Various Bioassays and with the Radioimmunoassay	201
GENAZZANI, A. R. (Siena): Clinical Applications of Human Chorionic Somatomammotropin (HCS) Radioimmunoassay	207
BURGER, H. G.; CAMERON, D. P.; CATT, K. J.; CONNELLY, J. F. and WETTENHALL, H. N. B. (Melbourne): The Clinical Significance of Immunoreactive Growth Hormone Measurements	217
ILLIG, R. and PRADER, A. (Zürich): Growth Hormone Antibodies in Patients Treated with Different Preparations of Human Growth Hormone (HGH).	226
ASSAN, R. (Paris): Glucagon Radioimmunoassay: Technical Problems and Recent Data.	233

VALLOTTON, M. B. (Geneva): Radioimmunoassays of Angiotensin I and II and Other Small Polypeptide Hormones	246
VALLOTTON, M. B. (Geneva): Radioimmunoassay of Angiotensin I and II for Clinical Evaluation of the Renin-Angiotensin System.	254
CATT, K. J.; CAIN, M. D. and ZIMMET, P. Z. (Melbourne): Radioimmunoassay of Angiotensin II	258
TEMLER, R. S. and FELBER, J.-P. (Lausanne): Radioimmunoassay of Enzymes of the Exocrine Pancreas (Trypsin, Chymotrypsin, Chymotrypsinogen and Carboxypeptidase A). Preliminary Results	267

Lipids

MALLEIN, R.; BRETTE, R.; SABATER, P. et BERTRAND, J. L. (Lyon): Etude biochimique des variations des lipides du foie dans les stéatoses traitées par le Tolbutamide	273
KLEINKNECHT, D.; LAUDAT, M.-H.; JUNGERS, P.; DUCROT, H. and LAUDAT, P. (Paris): Plasma and Urinary Lipids in Nephrotic Syndrome and Uremia	279
CARTON, M.; DESPEYROUX, T. M. et DOUSTE-BLAZY, L. (Toulouse): Lipides plasmatiques et peroxydes lipidiques au cours des syndromes de coagulation intravasculaire.	288
BACH, A. (Strasbourg): Hypoglycémie après ingestion de graisses à acides gras longs, moyens et courts. Essai d'interprétation métabolique	295
WAREMBOURG, H.; BISERTE, G.; JAILLARD, J.; SEZILLE, G. et SCHERPEREL, P. (Lille): Etude expérimentale chez l'homme et chez l'animal des perturbations lipidiques plasmatiques induites par l'alcool en perfusion intraveineuse	304
KATTERMANN, R. and WOLFRUM, D. J. (Göttingen): Lipid Metabolism in Experimental Hepatitis Induced by D-Galactosamine	313

Symposium: Problems of Detection of Metabolic Inborn Errors

CARSON, N. A. J. (Belfast): Disorders of Amino Acid Metabolism: Results of Screening Programmes in Northern Ireland	320
VIS, H. L. (Bruxelles): Techniques de détection des aminoacidopathies et des myopathies	330
COLLOMBEL, C.; KISSIN, C. et COTTE, J. (Lyon): Dépistage par des techniques fluorescimétriques de la phénylcétonurie et de la galactosémie	343

Miscellaneous

TATÒ, L. and RUBATELLI, F. F. (Padua): Menadione and Hemolytic Action of Snake Venom	358
TSUJI, M.; NISHIWAKI, J. and YAMADA, K. (Nagoya): Transport of Vitamin B ₆ in Human Erythrocytes and in Ascites-Sarcoma Cells	362

BOUNAMEAUX, Y. (Bâle): Exploration fonctionnelle des plaquettes. Description d'un test original.	374
LEWIS, J. P.; MOORES, R. R.; GARDNER, E., Jr.; ALFORD, D. A.; NEAL, W. A.; WELCH, E. T.; WRIGHT, C.-S. and SMITH, L. L. (Augusta, Ga.): Recent Advances in the Study of Erythropoietic Factors	384
LERSON, G. et DELWAIDE, P. (Liège): Méthode originale de mesure simultanée des clearances d'excrétion rénale du DTPA ^{140}La et de l'hippuran ^{131}I	398
AURELL, M. and DITZEL, J. (Gothenburg): Renal Clearance of ^{51}Cr -EDTA-Complex. A Comparison Between Continuous Infusion and Single Injection Techniques	405
PERCY-ROBB, I. W.; JALAN, K. N.; MCMANUS, J. P. A. and SIRCUS, W. (Edinburgh): Bile Salt Metabolism in Ileostomy Patients	414
ALLEGRI, G.; RUBALTELLI, F. F.; DE ANTONI, A. and LEVORATO, E. (Padua): Studies on Tryptophan Metabolism in Premature and Fullterm Newborn Babies	420
PAUNESCO, E. et STOINESCO, M. (Bucarest): Particularités biochimiques et immunologiques des structures lysosomales du leucocyte mononucléaire de l'organisme tuberculeux	430
MEUNIER, J. (Paris): Les dérivés de la phénothiazine et l'analyse toxicologique hospitalière d'urgence	438
MURRAY, E. F. and HORDYNSKY, W. E. (Orange, N. J.): Cisternal Fluid Potassium and Temperature Levels in Relation to Time of Death	447
FODOR, O.; SZANTAY, I. and COTUL, S. (Cluj): Action of Aspartic Acid on Protein Synthesis Amelioration in Chronic Hepatitis, Expressed by Se^{75} Albumin/ Se^{75} -Globulins Ratio.	452
KEPPLER, D.; BISCHOFF, E. and DECKER, K. (Freiburg i.B.): The Role of Uridine Nucleotides in Galactosamine Hepatitis	456
ECKERT-HUSEMANN, E. und BUSCH, Ch. (Marburg): Das klinische Bild der Mucopolysaccharidose dargestellt an 3 beobachteten Kindern	461
Authors' Index	473

Vol. 1: Methods in Clinical Chemistry

Photometric Methods

CARTER, P. (Wilmington, Del.): Direct Micro Determination of Serum Albumin with Bromcresol Purple	1
ELLIS, G. and GOLDBERG, D. M. (Sheffield): Necessity of Internal Standardisation in Colorimetric Determinations of Urine Hydroxyproline	10
ROOS, F. et SIEST, G. (Nancy): Réaction Créatine-Diacétyle: Avantages de l'addition d'Orcinol et de Glucuronolactone pour intensifier la réaction	21
SYMONOWICZ, N. and KOSZEWSKI, J. (Warsaw): The Use of Rapid Electronic Spectrophotometer in Clinical Chemistry	28
NAKAGAWA, H.; HEIRWEGH, K. P. M. and DE GROOTE, J. (Leuven): A New Urea Determination Based on Successive Treatments with Urease and <i>p</i> -Dimethylaminobenzaldehyde	35

Symposium on Fluorimetric Technics in Clinical Chemistry

WALKER, P. G. (Stanmore): Fluorescence Assays in Clinical Enzymology (Abstract)	41
ROBINSON, D. (London): Fluorimetric Detection and Assay of Kidney and Urinary β -Glycosidases	42
Discussion	51
MOSS, D. W. (London): Spectrofluorimetric Methods in the Characterization of Phosphatases from Human Tissues	53
Discussion	59
ROTH, M. (Geneva): Fluorimetric Assay of Bilirubin and of Vitamin C	61
Discussion	63
MUEHLBAECHER, CLARA A. and SMITH, ELIZABETH K. (Seattle, Wash): A New Reagent for Fluorimetric Measurement of 11-Deoxycortisol	65
Discussion	70
Round Table Discussion on Fluorimetric Technics in Clinical Chemistry	71

Electroanalysis

PURDY, W. C. (College Park, Md.): The Potential of Electroanalytical Chemistry in Clinical Investigation	82
MAAS, A. H. J. and MERTENS, P. J. (Utrecht): The Measurement of the P_{CO_2} and P_{O_2} of Blood with Electrodes in an Open Cuvette System	98
RAY, C. D. (Basel): Recent Trends in Ion-Selective Electrodes: A Brief Review	108
SAMBUCETTI, C. J. and NEFF, G. W. (Yorktown Heights, N.Y.): Galvanic Glucose Monitor	118

Proteins

FREI, P. C. (Lausanne): A New Modification of the Radial Immunodiffusion Method for Quantitative Serum Protein Measurements	124
KRØLL, J.; JENSEN, K. A. and LYNGBYE, J. (Copenhagen): Quantitative Immunoelectrophoresis as Routine Analysis	131
STABILINI, R.; BRAGOTTI, R.; MARASINI, B.; SBAFFI, A. and AGOSTINI, A. (Milan): Immunochemical Quantitation of Plasminogen	140
BECKER, W.; HEIMBURGER, N.; SCHWICK, H. G. and STÖRIKO, K. (Marburg/Lahn): Immunological Determination of Biologically Active Plasma Proteins	144
HOFFMEISTER, H.; ABRAHAM, K.; MÜLLER, I. und SCHÜTT, K. (Hamburg): Zur Quartärstruktur der Haptoglobine in normalen und pathologischen Humanseren. Untersuchungen mit der kontinuierlichen Polyacrylamid-Elektrophorese	152
WATSON, P. J. and LOBSTEIN, O. E. (Lafayette, Ind.): Our Experience with the Millipore (TM) System and Densitometer, and the Titan III (TM) for Routine Electrophoresis	163
FISCHER, A.; VAJDA, L. and POLNER, A. (Budapest): Combination of Gel-Filtration with Ion-Exchange Chromatography for the Separation of Protein Fractions in Body Fluids	167

Drugs

167

- ABRAHAMSSON, L. and WASSÉN, A. M. (Uddevalla): Group Separation Methods for Identification of Drugs in Blood and Urine 171

Automation

- MITCHELL, F. L. (London): Present and Future Trends of Automation in Clinical Chemistry 180
- JUNGNER, I. (Stockholm): Calibration and Standardization of the AutoChemist with Computer Assist. 191
- KÜFFER, H.; COLOMBO, J. P. and RICHTERICH, R. (Bern): A New Approach to Laboratory Automation. 202
- THOMPSON, W. P.; WILLARD, R. E. and WILCOX, R. (Loma Linda, Calif.): Clinical Evaluation of Beckman's Discrete Sample Analyzer 207
- RILEY, C. (London): Considerations in the Basic Philosophy of the Vickers Automatic Analysis Machine 214
- BOWDEN, K. F. and JONES D. M. (Colchester): The Data Processing Aspects of the Vickers Multichannel 300. 218
- WERNER, M. (San Francisco, Calif.): On-Line Monitoring of Autoanalyzers by a Clinical Laboratory Computer System 226
- KADISH, A. H. and LITTLE, R. L. (Los Angeles, Calif.): Automation Control of Blood Glucose Homeostasis. 231
- BOLD, A. M. (London): Measurement of Dialysable Calcium. 241
- DELBRÜCK, A. (Hannover): A New Approach to the Problem of Identification in Automated Clinical Chemistry. 246
- KIND, P. R. N.; MORGAN, E. A.; BIGNALL, A. H. C. and GOLDBERG, I. J. L. (London): Experience with Simplified Continuous Flow Techniques with Particular Reference to Multiple Analysis for Urea and Electrolytes 250

Quality Control

- BÜTTNER, H. (Hannover): Quality Control and Standardization of Clinical Chemical Methods 260
- JONNARD, R. (Paramus, N. J.): Simple Quality Control System for Accuracy Correction of Analytical Results 263
- TRAVERSE, DE, P. M.; HENROTTE, J. G. et DEPRAITERE, R. (Paris): La collecte et la conservation des échantillons dans les recherches de biochimie des populations 296
- VANZETTI, G. and PALAZZI, D. (Milano): A Regional Program of Quality Control for Assessment of the Analytical Performance of Laboratories. 307
- HOLTZ, A. H. (Utrecht): Development of International Haemoglobinometry Standardization 315
- Authors' Index. 320

Vol. 2: Clinical Enzymology

Symposium on Erythrocyte Enzymopathology

KAPLAN, J. C. and KISSIN, C. (Paris and Lyon): Inherited Abnormalities of Red Cell Glycolytic Enzymes	1
PRANKERD, T. A. J. (London): Methaemoglobinaemia.	19
RAMOT, B. (Tel-Aviv): Glucose-6-Phosphate Dehydrogenase Variants and its Clinical Implications	23

Symposium on Proteases Inhibitors

WERLE, E. (München): Proteaseninhibitoren – Bedeutung für Forschung und Klinik	32
VAIREL, E. G. et FORLOT, P. (Paris): Evolution du pouvoir inhibiteur du sang vis-à-vis de certains enzymes au cours de syndromes d'hypercoagulation	40
JOSSO, F.; BENAMON-DJIANE, D.; LAVERGNE, J. M.; WEILLAND, C. and STEINBUCH, M. (Paris): Investigation of Plasma Antithrombin Activity Using ^{125}I -Labelled Human Thrombin	46
FRITZ, H. (München): Proteaseninhibitoren: Nachweis, Isolierung, Hemmechanismen	53
HOCHSTRASSER, K. (München): Hemmzentren von Proteaseninhibitoren.	57
STEINBUCH, M. and REUGE, C. (Paris): Variation of the Activity of α_2 -macroglobulin as Progressive Antithrombin after Molecular Modification	61
COUNITCHANSKY, Y.; BERTHILLIER, G. et GOT, R. (Lyon): Sur la formation d'un complexe entre les immunoglobulines IgA du colostrum humain et la trypsine	67
FINK, E. (München): Isolierung eines Trypsininhibitors und zweier Trypsin-Plasmin-Inhibitoren aus den Samenblasen von Meerschweinchen	74
BIETH, J.; MIESCH, F. et MÉTAIS, P. (Strasbourg): Corrélation entre la capacité d'inhibition protéasique et le taux d' α_1 -antitrypsine et d' α_2 -macroglobuline des liquides d'ascite et pleuraux	77

*Communications**a) Methods of Enzyme Determination*

DORCHE, C.; KISSIN, C.; COLLOMBEL, C.; MATHIEU, M.; ROLLAND, M. O. et COTTE, J. (Lyon): Etude de la conservation du sang capillaire prélevé sur papier pour le dosage de la galactotransférase et de la glucose-6-phosphate deshydrogénase. .	82
GLATZLE, D. (Basle): Dependency of the Glutathione Reductase Activity on the Riboflavin Status	89
ELLIS, G.; BELFIELD, A. and GOLDBERG, F. M. (Sheffield): An NADH-linked Kinetic 5'Nucleotidase Assay.	95
PERSIN, J. P. and VAN DER SLIK, W. (Amsterdam and Leiden): A New Method for the Determination of Serum Nucleotidase.	108

PRAGAY, D. A. and CHILCOTE, M. E. (Buffalo and New York): Clinical Evaluation of a New Amylase Method Using Amylose Azure (Remozal Brilliant Blue Amylose) Substrate	113
ROMAN, W. and RUYS, J. (Adelaide): The Colorimetric Estimation of Arginase in Serum	121

b) Enzymes in Pathology

STAAL, G. E. J.; HELLEMAN, P. W.; WAEL, J. DE and VEEGER, C. (Utrecht and Wageningen): Properties of Glutathione Reductase (E.C.1.6.4.2.) from Normal Erythrocytes and from Erythrocytes of a Patient with a Glutathione Reductase Deficiency	129
CARTIER, P.; NAJMAN, A.; KAMOUN, P. et LEROUX, J. P. (Paris): Anémies hémolytiques congénitales avec inclusions intra-érythrocytaires et ATP bas. Etude de deux familles	133
CARTIER, P.; TEMKINE, H. et GRISCELLI, C. (Paris): Etude biochimique d'une anémie hémolytique avec déficit familial en phosphohexo-isomérase	139
KISSIN, C. and COTTE, J. (Lyon): The Possibility of the Existence of a Variety of Glucose-6-phosphate Dehydrogenase Peculiar to the Algerian Race: Glucose-6-phosphate Dehydrogenase Type Debrousse	144
WILLIG, F.; SCHMIDT, F. H. und STORK, H. (Mannheim): Proteinchemische und enzymatische Analyse von Pankreascystensaft	150
RIBET, A.; PASCAL, J. P.; VAYSSE, N.; AUGIER, D. et THOUVENOT, J. P. (Toulouse): Relations entre le taux des protéines totales et l'activité des enzymes dans le suc duodénal humain normal et pathologique.	155
MATHIEU, M. et COTTE, J. (Lyon): Etude critique des tests de détection et d'identification des erreurs innées du métabolisme du glycogène (à propos de 17 cas de glycogénoses).	163
BROWN, S. S.; PROUDFOOT, A. T.; RAEBURN, J. A. and WRIGHT, N. (Edinburgh): Elevation of Serum Enzyme Levels in Acute Poisoning	173
TRYDING, N.; TUFVESSON, G. and NILSSON, S. E. (Kristianstad): Influences on Serum Monoamine Oxidase (MAO) and Diamine Oxidase (DAO) Activity	183
DEMELIER, J. F.; BARK, C.; LABAT, J. et COURTOIS, J. E. (Paris): Activités tréhalasiques du sérum et de l'urine chez l'homme.	187
VINCENT, D.; PLAUCHU, M. et GIRARD, M. (Lyon): Cohlinestérase et arylestérase sériques dans le diabète.	195
Authors' Index.	203

Vol. 4: Digestion and Intestinal Absorption

Plenary Lectures

DESNUELLE, P. (Marseille): Adaptation de la biosynthèse des enzymes du pancréas exocrine à des facteurs alimentaires et hormonaux	1
SEMENZA, G. (Zurich): In Search of Molecular Mechanisms in Intestinal Sugar Absorption	3

Symposium on Digestion and Intestinal Absorption

CRANE, R. K. (New Brunswick, N. J.): Functional Organization at the Brush Border Membrane.	23
PETERS, T. J.; HOFFBRAND, A. V. and BOOTH, C. C. (London): Subcellular Localization of the Digestive and Absorptive Functions of the Enterocyte	31
AURICCHIO, S. and CICCIMARRA, F. (Naples): Glucamylolytic Digestion of Starch in Human Intestinal Mucosa	45
GRAY, G. M. (Stanford, Calif.): Human Intestinal β -Galactosidases and Lactase Deficiency	51
BORGSTRÖM, B. (Lund): Intestinal Function of Bile	59
GITZELMANN, R.; BÄCHI, Th.; BINZ, H.; LINDENMANN, J. and SEMENZA, G. (Zurich): Cellular Localization of Rabbit Intestinal Sucrase	70
LAUNIALA, K. (Helsinki): A Study of Lactase Deficiency in the Finnish Population	74
Discussion	76
DAHLQVIST, A. (Lund): Intestinal β -Galactosidases	77
Discussion	80
KRAML, J. (Prague): Immunochemical Studies on the β -Galactosidases and Sucrases of the Small Intestine of the Rat.	81
Discussion	92
FÉRARD, G. et MÉTAIS, P. (Strasbourg): Modification du test au D-xylose. Son intérêt dans l'exploration fonctionnelle de l'intestin grêle.	97
Discussion	106
DAHLQVIST, A. (Lund): The Intestinal Mucosa in Glucose-galactose Malabsorption	108
Discussion	113
TABAQCHALI, S. (London): Case Study of a Patient with Massive Intestinal Resection	119
Discussion	123

Contributed Paper

KAHAN, J. (Stockholm): The Vitamin-A Absorption Test. A Survey of 547 Cases	124
Index of Authors and Discussants	134

Hormones

7th int. Congr. clin. Chem., Geneva/Evian 1969; vol. 3: Hormones, Lipids and Miscellaneous, pp. 1-5 (Karger, Basel/München/Paris/New York 1970)

Endocrine Abnormalities in Human Breast Cancer

M. W. RUCHELMAN and D. E. ANDERSON

Department of Medicine and Department of Biology, The University of Texas M. D.,
Anderson Hospital and Tumor Institute at Houston, Houston, Tex.

Many investigations have been conducted to determine what factors are associated with breast cancer. These have included socioeconomic factors, familial aggregation, endocrine function, and more recently, urinary steroid excretion patterns. No previous study has attempted to coordinate these various factors in an integrated way.

The present report describes a study directed to families in which two or more members have already developed breast cancer and where the family members are being subjected to clinical, radiographic, pathologic, and endocrine evaluations. This combined approach has high promise for identifying family members with early lesions of breast cancer or possibly those who may be at high risk for the subsequent development of the disease. The resulting data should also have utility in evaluating the genetic aspects of breast cancer and, specifically, whether the disease is comprised of one or more subtypes, which might be distinguishable by genetic, pathologic, radiologic, and/or endocrine criteria.

Only preliminary results are presently available. These pertain to clinical and pathologic characteristics of 399 patients with family histories of breast cancer among a total of 5,775 such cancer patients on file at The University of Texas M. D., Anderson Hospital and Tumor Institute at Houston, for the period from 1944-1967.

In a comparison of these two groups of patients with and without family histories of breast cancer, ANDERSON [1968] found differences with regard to: (1) age of first admission (the closest approximation to the age at onset); (2) tumor classification; (3) two different histories of obesity, hypertension, and diabetes within the familial group itself; and (4) lesion multiplicity. Familial patients with breast cancer had a younger age distribution and an

earlier average age at first admission than did non-familial patients. A young age has also been found to characterize other genetic varieties of neoplasms, whose average ages at onset are markedly earlier than the same neoplasms occurring sporadically in the general population.

It was noted in this study that familial patients with a history of obesity, hypertension, and/or diabetes had a distinctly older age distribution than did the 221 familial patients without these findings. The age distribution in the obese, hypertensive, diabetic group corresponded with the post-menopausal period. The age distribution in the other group without these findings corresponded with the pre-menopausal or post-menopausal periods.

Familial patients were also found to have an excess number of medullary carcinomas and more intraductal and lobular carcinomas than non-familial patients.

Another difference was that the familial group had significantly more bilateral occurrences of breast cancer than the non-familial group, a finding in keeping with other genetic cancers, which are also characterized by multiple and bilateral lesions.

The findings thus indicate the interesting possibility of at least two hereditary varieties of breast cancer: an early type which may be associated with ovarian estrogens and/or androgen insufficiency; and an older group with an adrenocortical imbalance. The endocrine part of this study, therefore, is extremely important in evaluating this possibility.

For many years, the modification of the internal steroid environment by endocrine ablation and hormone administration has continued to be a mainstay in breast cancer therapy. Palliation consists of removing the ovaries, the adrenals, or the pituitary, either singly or in combination. Hormones are also discriminatingly administered. Steroids, and estrogens in particular, are known to influence the growth of normal and neoplastic mammary tissue.

In a study in England, BULBROOK and HAYWARD [1967] showed abnormal urinary excretion patterns of the steroid hormones in breast cancer patients. They expressed this variance as a weighted deviation of etiocholanolone and corticosteroids. Their data were determined prior to the onset of clinical signs of breast cancer. However, of 22 cases of breast cancer which were later detected in a prospective study of 5,000 women, 18 had abnormal steroid patterns prior to the development of breast cancer. Since then, three more breast cancers with abnormal steroid patterns have appeared [BULBROOK, 1968]. However, BULBROOK [1966] conceded that several other factors could

influence the predictions, including the interval between mastectomy and reappearance of disease, age, menopausal status, and nationality.

LEMON *et al.* [1966] believe that attempts to demonstrate differences in the ratio of non-carcinogenic estriol to carcinogenic estrone and estradiol between breast cancer cases and controls have been inconclusive. They feel that the discrepancy in results obtained by different investigators is the result of differences in the methods and the timing of patient selection for study. They themselves find a marked increase in the urinary quotient of estriol/estrone+estradiol among normal women as opposed to those with breast cancer. With repeated pregnancy and later post-menopausal ovarian atrophy, it is likely that the quotient would rise in subnormal excretors and thus reduce the likelihood of late cancer. They suggest that normalization of a precancerous metabolic imbalance between impeded and active estrogens would also contribute to arrested growth of estradiol-dependent metastases.

The endocrine part of the present investigation is an extension of BULBROOK's studies with modifications and the inclusion of other hormones. The urinary steroid excretion patterns of women belonging to families in which two or more cases of breast cancer have already occurred will be compared with controls. The controls consist of females from the general population of the Texas Medical Center and without a family history of breast cancer, but matched for age, marital status, parity, and menstrual history to those in the familial series. Thermograms and mammograms have already been completed on the controls and have just begun on the familial women. The latter will have, in addition, physical breast examinations.

For endocrine analyses, a 24-h urine sample is requested. The 17-ketosteroid determination is by the RUCHELMAN and COLE [1966] method, utilizing gas chromatography. This consists of mild hydrolysis with sulfuric acid, followed by extraction, sodium hydroxide wash, drying, and evaporation of solvent. Derivatives (trimethylsilyl ethers) are formed for gas chromatography, on a 12 ft $\times$ 4 mm glass column of 4% XE-60 phase, with automatic sample injection [RUCHELMAN, 1966]. A computer program is in the process of being written to cover these urinary determinations.

Corticosteroids are being analyzed by a modification of the PETERSON *et al.* [1955] method, with enzymatic hydrolysis in a buffered solution, dichloromethane extraction, freezing out of the aqueous phase, and colorimetry of a phenylhydrazine-reacting group.

A procedure for low-level estrogens is presently being developed in this laboratory, consequently, aliquots of urine are being frozen for future use.

This method will entail hydrolysis by a mixed glucuronidase-sulfatase enzyme preparation, extraction with ether, then sodium hydroxide. Thin-layer chromatography will remove interfering substances prior to whole-sample injection of the estrogens as free steroids on gas chromatography. The quantitation will be similar to that elaborated in the solubility studies of RUCHELMAN [1969] of the three major estrogens, where no derivatives were used for gas chromatography.

Future plans call for evolving a new method of analysis of hydroxycorticosteroids by gas chromatography, involving fractionation into individual components for discerning true patterns.

MEYER [1967] points out that the new technologic developments permit a rapid, accurate analysis of detectable steroid differences between patients. This gives assurance that future research will lead to predictions of response.

Among the hormone steroids, specific chemical anomalies may be best detected by a discriminant function [similar to that described by BULBROOK], or by a ratio, either of which could consist of a combination of androgens and hydroxycorticosteroids, of androgens and estrogens, or of estrone, estradiol, and estriol alone.

Possibly, also, some endogenous combination of hormones may produce a completely new type of steroid that may be present in the urine of these high-risk individuals. This could be present as a metabolite of the osteolytic steroid, the 'spreading factor' found in sera of a number of breast cancer patients by BROWN and MARRACK [1968].

As previously pointed out, gas chromatography is the method of choice for detecting abnormalities in the steroids. If specific steroid abnormalities are detected in genetically high-risk women, this could have ultimate bearing on breast cancer control. It might then be possible to correct this endocrine abnormality during the initial stages of disease development before the disease becomes irreversible.

Summary

This is a prospective-type study with a twofold purpose: (1) evaluation of endogenous hormonal steroids in concert with mammography and thermography in an attempt to detect and identify women with very early lesions of breast cancer; and (2) correlation of endocrine, histologic, and radiologic data with genetic data in order to clarify the role of genetic factors and to discriminate high-risk families.

Soon endocrine anomalies may be recognized early enough to have ultimate bearing on breast cancer control at the initial stages of the disease.